AI service Tevogen.AI accelerates market entry through AI-driven patient matching, post the launch of PredicTcell Alpha.
**Tevogen.AI: Revolutionizing the ExacTcellTM Pipeline with AI and Real-World Data**
Tevogen Bio, a pioneering biotechnology company, has announced the expansion of Tevogen.AI, an AI-driven target discovery platform designed to accelerate the development of its ExacTcellTM immunotherapy platform. The platform integrates advanced machine learning and predictive modeling, using electronic health records (EHRs) and real-world patient data to streamline the drug discovery process [1].
At the heart of Tevogen.AI is the PredicTcell™ suite, which employs sophisticated AI algorithms to analyse vast datasets, including genetic and proteomic data from EHRs and other real-world sources, to predict immunologically active peptide-T cell receptor interactions [1][2]. This acceleration in target discovery significantly expedites the preclinical phase, allowing Tevogen Bio to identify and prioritise immunotherapy candidates for the ExacTcellTM pipeline much faster than conventional methods [2][4].
One of the key advantages of Tevogen.AI is its ability to enhance patient matching for clinical trials. By analysing EHRs and real-world patient data, the platform precisely matches patients with clinical trials, using AI to parse medical histories, biomarkers, and other clinical criteria [3][5]. This streamlined patient recruitment shortens trial initiation times and increases enrollment efficiency, which are significant bottlenecks in drug development [3][5].
Moreover, Tevogen.AI's predictive modeling capabilities can forecast potential adverse drug reactions and efficacy concerns early in development, enabling timely adjustments and reducing the risk of costly trial failures [1]. In-silico experiments, powered by platforms like AdapTcell™, further deepen understanding of immune system interactions, informing genetics and proteomics research for more targeted therapies [1].
By leveraging real-world data and AI, Tevogen.AI aims to generate billions in cost savings across the healthcare system, not only by reducing lab dependency but also by streamlining the entire drug development process [2][4]. The platform’s expansion into oncology and other therapeutic areas, powered by its growing terabyte-scale database, positions Tevogen Bio to rapidly scale its immunotherapy pipeline and respond to emerging medical needs [2].
In summary, Tevogen.AI's integration of machine learning with real-world patient data and EHRs enables rapid, data-driven decision-making across the ExacTcellTM pipeline—from target discovery to clinical trial optimization. This approach not only accelerates development timelines but also aims to reduce costs and improve the likelihood of successful, patient-centric immunotherapy treatments [1][2][3].
Tevogen Bio's contact information for communications is available: T: 1 877 TEVOGEN, Ext 701, [email protected].
*This news article is based on a press release from Tevogen Bio, as reported by GlobeNewswire via QuoteMedia.*
*Factors such as the need to raise additional capital, changes in market conditions, and regulatory risks may affect Tevogen's actual results.*
*Tevogen.AI is supported by Microsoft and Databricks.*
*Tevogen Bio's press release contains forward-looking statements regarding its research and manufacturing capabilities, growth expectations, and product development plans.*
- Tevogen.AI, integrated with advanced AI and real-world patient data, intends to revolutionize the health-and-wellness sector by generating cost savings and streamlining the entire drug development process, particularly in the onset and treatment of medical-conditions like immunotherapy for oncology.
- The utilization of artificial-intelligence algorithms in Tevogen.AI's PredicTcell™ suite enables the accurate prediction of immunologically active peptide-T cell receptor interactions, facilitating the discovery of potential targets for health-and-wellness products such as Tevogen Bio's ExacTcellTM immunotherapy platform.
